COVID-19

BioNTech SE and Pfizer Inc disclosed additional details of their collaboration to advance candidates from BioNTech’s mRNA vaccine program, previously announced on March 17, 2020.

The U.S. Food and Drug Administration issued an emergency use authorization for a blood purification system to treat patients 18 years of age or older with confirmed Coronavirus Disease 2019 (COVID-19) admitted to the intensive care unit (ICU) with confirmed or imminent respiratory failure.

There will not be any shortage of hydroxychloroquine in the country either today or in the future. Community support plays an important role in helping to identify cases early which in turn is key to containing spread and mortality due to COVID-19. States have started providing assistance to building and construction sector workers, as per the component under Rs. 1.7 lakh crore Pradhan Mantri Garib Kalyan Yojana package : Union Home Affairs Ministry.

CSIR-Central Electrochemical Research Institute (CECRI), a premier research establishment under the aegis of Council of Scientific and Industrial Research (CSIR), New Delhi, focussing on a gamut of problems covering all facets of electrochemical science and technology: viz., Corrosion Science and Engineering, Electrochemical Power Sources, Electrochemical Materials Science, Electro-organic and Electro-inorganic Chemicals, Electrodics and Electrocatalysis, Electro-metallurgy, Electro Plating and Metal Finishing Technology. CSIRCECRI's activities are directed towards the development of new and improved products and process as well as innovations in electrochemical science and technology. CSIR-CECRI runs several projects in collaboration with laboratories and private companies within and outside India.

Three classes of facilities to be set up for various categories of COVID-19 patients: Health Ministry’s guidance document for managing COVID-19, Government strategy for cluster containment and for managing outbreaks yielding positive results in some areas : Union Health Ministry

The continued availability of medicines, in particular those used for patients with COVID-19, is of critical concern for EMA and its partners in the European medicines regulatory network in light of the medical emergency presented by the pandemic.